Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT): Price and Financial Metrics
Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT)
Today's Latest Price: $5.84 USD
Updated Dec 2 4:00pm
Add OSMT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
OSMT Stock Summary
- Osmotica Pharmaceuticals plc's stock had its IPO on October 18, 2018, making it an older stock than merely 4.92% of US equities in our set.
- With a year-over-year growth in debt of -18.71%, Osmotica Pharmaceuticals plc's debt growth rate surpasses only 15.68% of about US stocks.
- Revenue growth over the past 12 months for Osmotica Pharmaceuticals plc comes in at -17.31%, a number that bests just 20.58% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Osmotica Pharmaceuticals plc are ORBC, LIVN, OPK, SANW, and SCOR.
- OSMT's SEC filings can be seen here. And to visit Osmotica Pharmaceuticals plc's official web site, go to www.osmotica.com.
OSMT Stock Price Chart Interactive Chart >
OSMT Price/Volume Stats
| Current price | $5.84 | 52-week high | $9.67 |
| Prev. close | $5.82 | 52-week low | $2.81 |
| Day low | $5.72 | Volume | 131,042 |
| Day high | $5.96 | Avg. volume | 383,750 |
| 50-day MA | $5.77 | Dividend yield | N/A |
| 200-day MA | $5.36 | Market Cap | 300.88M |
Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio
Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.
OSMT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $5.84 | $0.25 | -96% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Osmotica Pharmaceuticals plc. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 6th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 96%. The most interesting components of our discounted cash flow analysis for Osmotica Pharmaceuticals plc ended up being:
- The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 16.84% of free cash flow generating stocks in the Healthcare sector.
- The company's compound free cash flow growth rate over the past 2.11 years comes in at -0.31%; that's greater than merely 4.69% of US stocks we're applying DCF forecasting to.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -96% |
| 1% | -96% |
| 2% | -96% |
| 3% | -96% |
| 4% | -96% |
| 5% | -96% |
NVST, LUMO, INFU, PHG, and PPD can be thought of as valuation peers to OSMT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...